Glutamate Activity in Depression (GLADE)

Overview

A brain chemical (neurotransmitter) called glutamate is thought to play an important role in the causation and treatment of depression. It is possible to measure glutamate in the brain in people, using safe magnetic resonance imaging but results of studies of glutamate levels in people with depression and those at risk of depression have been inconclusive. We have devised a method whereby viewing a flashing light for a few minutes provides a measure of stimulated glutamate release. We believe that this kind of functional measure is more relevant physiologically because studies in animals show that glutamate release evoked by sensory stimulation represents release of glutamate as a neurotransmitter rather than glutamate in intermediate metabolism. Therefore, the use of functional magnetic resonance spectroscopy (fMRS) may provide a more useful measure of neural glutamate activity in people with depression and those at risk of depression. The aim of this study is to look at the effect of a flashing light on glutamate release in people who have recovered from depression and compare it to people who have not experienced depression. We hope from this to discover whether changes in glutamate activity might be a risk factor for the development of depression. This could be helpful both for diagnostic purposes and for the development of medications that can relieve depression by modifying glutamate release.

At the screening visit, potential participants will be asked about their medical history. This will include an SCID interview to ascertain history of psychiatric disorder and PHQ-9 questionnaire to ascertain the presence of any depressive symptoms. They will be asked about their lifestyle (for example, smoking, caffeine and alcohol consumption), and questions that pertain to magnetic resonance imaging (MRI) safety. These are carried out to ensure that the participants meet the study and safety criteria. The criteria will be assessed by a member of the research team and the participant will only be allowed to continue if they meet all the requirements. The duration between screening and the research visit should not exceed 3 months and MRI safety questions will be repeated on the day of participation, prior to the participants entering the MRI scanner. The participants who have been screened and confirmed eligible for the study, will be invited for a scanning visit. During this visit, the participant will then be asked to lie down on the scanner bed where they will be attached to physiological monitors (i.e. pulse oximeter and respiration belt). Once the participant is comfortable to begin scanning, the radiographer will begin the relevant scan protocol which consists of different MR sequences aimed at imaging different structural and functional properties of the brain. At the start of the scan, structural MRI images will be acquired which lasts approximately 5 minutes, participants may watch a visual presentation to remain alert. Once structural scans are completed, the fMRS paradigm will begin which includes three block conditions with fMRS acquisitions taken during each block. The blocks conditions will consist of a \~11 minute rest block, followed by a \~5 minutes and 30 seconds flickering checkerboard block and a final \~11 minute rest block. After this we will carry out a 'resting state' fMRI to measure the brain activity during rest. Participants will be asked to close their eyes during rest periods and have them open for the flickering checkerboard stimulus, these instructions will be told to them through the radiographer intercom. Once the fMRS and resting state acquisitions are completed, the participant will be told by the radiographer that their scan is complete and they will be assisted out of the scanner. The total scanning duration will last for not more than 60 minutes. Overall, the screening assessment should take about 1 hour and scanning visit will take about 90 minutes.